Latest KFF Health News Stories
Helene and CVS Land Double Whammy for 25,000 Patients Who Survive on IV Nutrition
A Massachusetts woman ended up stranded in the hospital because CVS stopped providing the IV nutrition she needs to survive at home. Without it, she’d starve.
Colorado’s Naloxone Fund Is Drying Up, Even as Opioid Settlement Money Rolls In
Since Colorado created a pool of money to pay for naloxone in 2019, it has distributed more than half a million doses of the opioid reversal drug to hundreds of organizations throughout the state. Now, its main funding stream is drying up.
KFF Health News' 'What the Health?': Yet Another Promise for Long-Term Care Coverage
As part of her presidential campaign, Vice President Kamala Harris has rolled out a plan for Medicare to provide in-home long-term care services. The proposal would fill a longtime need for families trying to simultaneously care for young children and older parents, but its enormous price tag makes it a promise unlikely to be fulfilled. Meanwhile, a growing number of Republican candidates up and down the ballot facing voter backlash over their support for abortion restrictions are trying to reinvent their positions. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, excerpts from a KFF lunch with “Shark Tank” panelist and generic drug discounter Mark Cuban, who has been consulting with the Harris campaign about health care issues.
Employers Haven’t a Clue How Their Drug Benefits Are Managed
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
Calif. Ballot Measure Targets Drug Discount Program Spending
Californians in November will weigh in on a ballot initiative to increase scrutiny over the use of health-care dollars — particularly money from a federal drug discount program — meant to support patient care largely for low-income or indigent people. The revenue is sometimes used to address housing instability and homelessness among vulnerable patient populations. Voters […]
What’s New and What To Watch For in the Upcoming ACA Open Enrollment Period
This year’s start date in most states is Nov. 1, and consumers may encounter new scams as well as important rule changes.
Harris Correct That Trump Fell Short on Promise To Negotiate Medicare Drug Prices
The former president instead favored a temporary model that could’ve brought down prices of some prescription drugs, but it was blocked by the courts.
Setting the Record Straight on the FDA’s Authority Over Drug Ads
KFF Health News gives readers a chance to comment on a recent batch of stories.
How Minnesota Figures Into the Presidential Politics of Insulin Prices
Minnesota led the way on insulin affordability, culminating in 2020 when Gov. Tim Walz signed a law going further to cut costs than other state laws. Now, former President Donald Trump and Vice President Kamala Harris are vying for support from people with diabetes.
KFF Health News' 'What the Health?': Congress Punts to a Looming Lame-Duck Session
Congress left Washington for the campaign trail this week, but not before approving a spending bill that expires shortly before Christmas. Lawmakers will be busy after the election working on not just the legislation needed to keep the government running, but also several health programs set to expire. Meanwhile, Republicans continue to downplay abortion as Democrats press it as a campaign issue. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more.
KFF Health News' 'What the Health?': American Health Under Trump — Past, Present, and Future
Dreaming of a Trump victory, Republicans have a wish list of health policy changes — including loosening Affordable Care Act regulations to make cheaper coverage available and ending Medicare drug price negotiations. Meanwhile, after a publicly reported death stemming from a state abortion ban, Vice President Kamala Harris is emphasizing the consequences of Trump’s work to overturn Roe v. Wade. Tami Luhby of CNN, Shefali Luthra of The 19th, and Joanne Kenen of Politico and Johns Hopkins University join KFF Health News senior editor Emmarie Huetteman to discuss these stories and more.
Harris and Trump Are Ready To Take on Big Pharma
Former president Donald Trump and Vice President Kamala Harris are both eager to take on high drug prices, leaving pharmaceutical companies on the defensive as they spend millions of dollars this election season. When Harris was California’s attorney general, she joined cases that resulted in almost $7.2 billion (about $22 per person in the United […]
For Pharma, Trump vs. Harris Is a Showdown Between Two Industry Foes
Vice President Kamala Harris is seen as more aggressive than former President Donald Trump in taking on pharmaceutical companies, but Trump allies say he would also make lowering drug costs a top priority.
Para las farmacéuticas, la pelea entre Trump y Harris es entre dos enemigos de la industria
Legisladores de ambos partidos atacan cada vez más a la industria, por los precios de los medicamentos que la mayoría de los estadounidenses consideran irrazonables.
Since Fall of ‘Roe,’ Self-Managed Abortions Have Increased
The percentage of people who say they’ve tried to end a pregnancy without medical assistance increased after “Roe v. Wade” was overturned. One of the most common reasons for seeking a self-managed abortion was privacy concerns.
Copycat Weight-Loss Drugs Are Major Players With Consumers
As many as 1 in 8 American adults has tried one of the GLP-1 anti-obesity drugs, but a surprising number aren’t getting their supplies from pharma giants Novo Nordisk or Eli Lilly. Up to 30 percent of the market, by some estimates, is made up of copycat versions from compounding pharmacies. Compounding is legal, though […]
KFF Health News' 'What the Health?': Harris in the Spotlight
For the 2024 campaign, Joe Biden is out, and Kamala Harris is in. As the vice president makes moves toward the top of the Democratic presidential ticket, health policy is resurging as a campaign issue. Meanwhile, Congress tries — and again fails — to make timely progress on the annual government spending bills as abortion issues cause delays. Alice Miranda Ollstein of Politico, Stephanie Armour of KFF Health News, and Rachel Cohrs Zhang of Stat join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Anthony Wright, the new executive director of Families USA, about his plans for the organization and his history working with Harris on health topics.
World-Famous Wall Drug Isn’t Immune From Challenges Facing Rural Pharmacies
Even as part of a popular South Dakota tourist attraction, an independent pharmacy serving locals, remote ranchers, and sightseers struggles with staffing and insurer payments.
Louisiana Reclassifies Drugs Used in Abortions as Controlled Dangerous Substances
Louisiana lawmakers have added two drugs commonly used in pregnancy and reproductive health care to the state’s list of controlled dangerous substances, a move that has alarmed doctors in the state.
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
